Brad Sitko - Chief Investment Officer @ XOMA

Overview

CB Rank (Investor)

Brad Sitko is the Chief Investment Officer of XOMA. Brad holds a BA from Penn and an MBA from Columbia Business School.

Number of Partner Investments

Announced Date	Organization Name	Investor Name	Lead Investor	Funding Round	Money Raised
obfuscated obfuscation	UroGen Pharma	RTW Investments	Yes	Post-IPO Equity - UroGen Pharma	obfuscated obfuscation

Number of Current Jobs

Number of Past Jobs

is the

Chief Investment Officer

. Additionally,

has had

past job as the

Vice President, Finance & Corporate Development

Organization Name	Title At Company	Start Date	End Date
DNAnexus	Vice President, Finance & Corporate Development	2015	2019

Hub Name	CB Rank (Hub)
Biotechnology Acquired Companies With Less Than $50M in Revenue	10,579
Therapeutics Acquired Companies With More Than 10 Employees	44,317
Developer Platform Companies With Fewer Than 100 Employees	20,702
Therapeutics Acquired Companies With More Than $10M in Revenue	86,828
Biotechnology Acquired Companies With Fewer Than 1000 Employees	7,820
Developer Platform Companies With Fewer Than 1000 Employees	17,474
Developer Platform Acquired Companies With More Than $1M in Revenue	100,629
Therapeutics Acquired Companies With Fewer Than 1000 Employees	42,782
Blue Owl Portfolio Companies	62,183
Therapeutics Acquired Companies With Less Than $500M in Revenue	100,890

There is no recent news or activity for this profile.